尽管顶线和底线都有节拍，但达维塔还是下跌了

2026-08-05 07:19

DaVita (DVA) is down ~7% in after-hours trading Tuesday despite releasing Q2 financial results that beat on both lines and maintaining its 2026 guidance.
Adjusted diluted EPS for the year is seen at $14.10-$15.20. Consensus is $14.88.
Q2 non-GAAP EPS of $4.02 compares to $2.95 in the year-ago period.
Although revenue per treatment in the quarter (ended June 30) fell $1.72 compared to Q1 to $415.87, patient care costs per treatment also fell $2.71 to $277.40.
In the quarter, the company repurchased 2.2M shares for $348M.
DaVita ended the quarter with cash, cash equivalents, restricted cash, and short-term investments of ~$771.8M compared to ~$782.1M on Dec. 31.

More on DaVita